TheraRadar
← Back
Data updated: Jul 17, 2026

SKYEPHARMA AG

Generics
Respiratory

SKYEPHARMA AG is a generic drug manufacturer focused on Respiratory.

1999
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

SKYEPHARMA AG's Key Drugs

SKYEPHARMA AG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SKYEPHARMA AG's Recent FDA Approvals

New NDA/BLA approvals for SKYEPHARMA AG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SKYEPHARMA AG's Therapeutic Areas

SKYEPHARMA AG's approved drugs and pipeline span 1 therapeutic area, led by Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 100%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1

SKYEPHARMA AG's Top Competitors

SKYEPHARMA AG's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Respiratory
Merck big-pharma
Respiratory
GSK big-pharma
Respiratory
Bayer big-pharma
Respiratory
B BRAUN specialty
Respiratory

SKYEPHARMA AG Pipeline Snapshot

SKYEPHARMA AG has 4 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 1 Phase 1.

2
Phase 3
1
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling